Bangkok Genomics Innovation Past Earnings Performance
Past criteria checks 1/6
Bangkok Genomics Innovation's earnings have been declining at an average annual rate of -57.2%, while the Healthcare industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 19.5% per year. Bangkok Genomics Innovation's return on equity is 13.6%, and it has net margins of 13.1%.
Key information
-57.2%
Earnings growth rate
-79.2%
EPS growth rate
Healthcare Industry Growth | 23.6% |
Revenue growth rate | -19.5% |
Return on equity | 13.6% |
Net Margin | 13.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Bangkok Genomics Innovation makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 245 | 32 | 84 | 0 |
31 Dec 22 | 305 | 75 | 93 | 0 |
Quality Earnings: BKGI has high quality earnings.
Growing Profit Margin: BKGI's current net profit margins (13.1%) are lower than last year (24.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if BKGI's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare BKGI's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: BKGI had negative earnings growth (-57.2%) over the past year, making it difficult to compare to the Healthcare industry average (-9.2%).
Return on Equity
High ROE: BKGI's Return on Equity (13.6%) is considered low.